Needle-free, inhalant powder measles vaccine

The first dry powder inhalable vaccine for measles is moving toward clinical trials next year in India, where the disease still sickens millions of infants and children and kills almost 200,000 annually, according to a report presented here today at the 238th National Meeting of the American Chemical Society (ACS).

If the inhaler passes final safety and effectiveness tests, the Serum Institute of India Ltd. expects a demand growing to 400 million doses of measles vaccine a year, according to Sievers.